This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Markel's Q2 Earnings Surpass Estimates, Premiums Rise Y/Y
by Zacks Equity Research
MKL tops Q2 earnings and revenue estimates, but profits dip as rising expenses weigh on margins.
International Markets and Danaher (DHR): A Deep Dive for Investors
by Zacks Equity Research
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Here's Why Danaher (DHR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of +9.76% and +1.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Danaher (DHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Danaher (DHR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Analyst Reports for Eli Lilly, Home Depot & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Danaher Partners With AstraZeneca to Support Precision Medicine
by Zacks Equity Research
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Consider Retaining Danaher Stock Now
by Zacks Equity Research
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
BLCO or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. DHR: Which Stock Is the Better Value Option?
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
by Zacks Equity Research
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 16.05% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.